FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)

View source ↗

Summary

FDA approved Biogen's supplemental application for TYSABRI (natalizumab). The action updates the product labeling to reflect the requested changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

SUPPL AP for TYSABRI (NATALIZUMAB)